Evidence map›Paper›PMID 27893694›Full record

ArticleMedicine2016

The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study.

Seung-Jun Lee, Jung-Hoon Sung, Jin-Bae Kim, Min-Soo Ahn, Hye Young Lee, Jae-Sun Uhm, Hui-Nam Pak, Moon-Hyoung Lee, Jong-Yun Kim, Boyoung Joung

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Optimal long-term antithrombotic management of atrial fibrillation: life cycle management.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2018
    Review
  5. [Current indications for left atrial appendage occlusion].Herzschrittmachertherapie & Elektrophysiologie · 2017
    Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Seung-Jun LeeDivision of Cardiology, Yonsei University College of Medicine, Seoul Division of Cardiology, Bundang CHA Medical Center, CHA University, Seongnam Division of Cardiology, Kyung Hee University College of Medicine, Seoul Division of Cardiology, Yonsei University Wonju College of Medicine, Wonju Division of Cardiology, Sanggye Paik Hospital, Inje University College of Medicine Division of Cardiology, Gangnam Severance Hospital, Seoul, Republic of Korea.
Jung-Hoon Sung
Jin-Bae Kim
Min-Soo Ahn
Hye Young Lee
Jae-Sun Uhm
Hui-Nam Pak
Moon-Hyoung Lee
Jong-Yun Kim
Boyoung Joung
Yonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the safety and efficacy of vitamin K antagonist (VKA) in atrial fibrillation (AF) patients with previous ulcer bleeding.In this multicenter, retrospective analysis, clinical outcomes of 754 AF patients with a history of ulcer bleeding were evaluated. After ulcer treatment, 458 patients (61%) were treated with VKA, and the outcomes were compared to 296 patients (39%) without VKA.VKA treatment significantly increased major bleeding (7.3%/year vs 3.2%/year, P < 0.001), and reduced major adverse cardiac events (MACE) (5.4%/year vs 10.0%/year, P < 0.001). Specifically, risk of gastrointestinal bleeding was significantly higher in the VKA group than no-VKA group (5.7%/year vs 2.6%/year, P < 0.001). Consequently, there was no difference in the incidence of composite of a MACE and major bleeding, between the 2 groups. In patients with time in the therapeutic range (TTR) ≥65%, VKA significantly decreased MACE (2.8%/year vs 10.0%/year, P < 0.001) without increasing major bleeding. Net clinical benefit model showed beneficial effects of VKA in patients with TTR ≥65%, and harmful effects in those with TTR < 55%.In AF patients with previous ulcer bleeding, VKA treatment did not improve clinical outcomes unless the international normalized ratio level was constantly maintained (TTR ≥65%), as the gastrointestinal bleeding (GIB) risk significantly increased.

Indexed as

AgedAtrial FibrillationFemaleHumansMaleMiddle AgedPeptic Ulcer HemorrhageRepublic of KoreaRetrospective StudiesRisk FactorsTreatment OutcomeVitamin KVitamin K

Identifiers

PMID27893694
PMCPMC5134887
OpenAlexW2549685865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.